Edwards Lifesciences (NYSE:EW) Sets New 1-Year High – Here’s Why

Shares of Edwards Lifesciences Corporation (NYSE:EW) hit a new 52-week high on Friday . The company traded as high as $89.48 and last traded at $86.2030, with a volume of 1470859 shares. The stock had previously closed at $87.45.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EW. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. BTIG Research boosted their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Barclays reiterated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Stock Performance

The stock has a 50-day simple moving average of $82.22 and a 200 day simple moving average of $83.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market capitalization of $49.53 billion, a PE ratio of 45.75, a P/E/G ratio of 2.16 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 95,057 shares of company stock valued at $7,874,217 over the last three months. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently made changes to their positions in EW. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at $25,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.